International Journal of Drug Delivery Technology
Volume 15, Issue 2

A Prospective Interventional Comparative Long-Term Study on the Safety of Canagliflozin and Dapagliflozin Depending on their ADR’s and Glucose Monitoring Parameters in a Tertiary Care Hospital for a Span of One Year 

Dhanush Bellapu, Ronald Darwin* 

Department of Pharmacology, Vels institute of Science, Technology and Advanced Studies (VISTAS), Chennai-600117, Tamil Nadu, India 

Received: 17th Mar, 2025; Revised: 15th Apr, 2025; Accepted: 25th Apr, 2025; Available Online: 25th Jun, 2025 

ABSTRACT

Introduction: SGLT2 inhibitors have a wide extent of restorative movement and higher chance of hypoglycaemia because of their affront autonomous action in treating type-2 Diabetes. SGLT2 inhibitors have great security and resistance when utilized as monotherapy or in conjunction with other oral hypoglycaemic medicines. Since SGLT2 inhibitors can cause hyperglycaemia, which results in vaginal and UTI contaminations. When compared, Dapagliflozin had higher contaminations. The key issue displayed is that ketoacidosis and that it may take a little time to analyse it.

Objectives: A careful comparison of Canagliflozin vs Dapagliflozin in terms of long-term urinary volume, renal function, and metabolic changes suggests that both are effective, but Dapagliflozin may have a slightly safer profile regarding fluid balance and tolerance in vulnerable populations. However, individual patient factors (e.g., baseline renal function, risk of volume depletion) must guide the choice.

Research methodology: A Planned Interventional Comparative Ponder conducted among 3452 patients who were conceded to in the General Medicine and Endocrine Departments, Anu Group of hospitals, Vijayawada over 12 months from December 2021 to December 2022. By alluding to the patient’s FBS and PPBS, RFT, HbA1c, BP, and the finding seriousness score of ADR (Adverse Drug Reaction) utilizing Naranjo scale.

Results: Patients had most common ADRs after Utilizing Canagliflozin and Dapagliflozin, were Hypotension and Dehydration respectively.

Conclusion: We concluded that in Patients had ADRs after utilizing Canagliflozin versus Dapagliflozin where hypotension and dehydration was more common respectively. ADRs in the Control population was weight pick up had the negative impact and Hypoglycaemia was found to be more in the Control population compared to Canagliflozin and Dapagliflozin endorsed bunches. Weight loss had a positive impact on Canagliflozin and Dapagliflozin-endorsed groups.

Keywords: Canagliflozin, Dapagliflozin, Dehydration, Hypotension, ADRs.

How to cite this article: Dhanush Bellapu, Ronald Darwin. A Prospective Interventional Comparitive Long-Term Study on the Safety of Canagliflozin and Dapagliflozin Depending on their ADR’s and Glucose Monitoring Parameters in a Tertiary Care Hospital for a Span of One Year. International Journal of Drug Delivery Technology. 2025;15(2):757-62. doi: 10.25258/ijddt.15.2.49

REFERENCES

  1. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al., Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systemic review and meta-analysis. Ann Intern Med. 2013 159:262-74
  2. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodium-glucose transporter 2 inhibition. Diabetes Care. 2015; 38:1730–5.
  3. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des DevelTher. 2014; 8:1335–80.
  4. Rosenstock J, Ferrannini E. Euglycaemic diabetic ketoacidosis: a predictable, detectable, and preventable concern with SGLT2 inhibitors. Diabetes Care. 2015; 38:1638–42.
  5. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015; 38:1687–93.
  6. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the Canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015; 38:1680–6.
  7. Inzucchi SE, Bergenstal RM, Buse JB, Dimant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centred approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38:140–9.
  8. Annamaria et. al. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary. Front Cardiovasc Med. 2022 Sep 21;9:1010693.
  9. Fitchett D et al. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation
  10. Donald S. Nelinson et al. SGLT2 inhibitors: a narrative review of efficacy and safety. Journal of Osteopathic Medicine. 2021 Feb 2; 121(2)
  11. Khawaja M Thala et al. SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence, Int J Heart Fail. 2023 Mar 13; 5(2): 82–90.
  12. Ryoma Kani et al. Racial and regional differences in efficacy of sodium-glucose cotransporter 2 inhibitors on cardiorenal outcomes: A systematic review and meta-analysis. International Journal of Cardiology 2025 May 1; Volume 426, 133079, ISSN 0167-5273, https://doi.org/10.1016/j.ijcard.2025.133079
  13. Daiji Kawanmi et al. SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy. J. Mol. Sci.2017, 18(5), 1083; https://doi.org/10.3390/ijms18051083
  14. Liu J, Lee T, DeFronzo R. Why do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans? Diabetes. 2012; 16:2199–204.
  15. Shrubawati Sarkar et.al. Contemporary Drifts in Diabetes Management, International Journal of Applied Pharmaceutics, 2023 March 7; Vol 15(2). https://doi.org/10.22159/ijap.2023v15i2.46792
  16. Chao EC, Henry RR. SGLT2 inhibition – a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010; 9:551–9.
  17. Hasan F, Alsahi M. Gerich SGLT2 inhibitors in the treatment of type 2 diabetes.Diabetes Res Clin Pract. 2014; 104:297–322.
  18. Jabbour SA, Hardy E, Sugg J, Parikh S, Study 10 Group. Dapagliflozin is effective as add-on therapy to Sitagliptin with or without metformin: a 24-week, multicenter, randomised, doubleblind, placebo-controlled study. Diabetes Care. 2014; 37:740–50.
  19. Sha S, et al. Pharmacodynamic differences between Canagliflozin and Dapagliflozin: results of a randomised, double-blind, crossover study. Diabetes Obes Metab. 2015; 17:188–97.
  20. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, Parikh SJ. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52- week, double- blind, active-controlled noninferiority trial. Diabetes Care. 2011; 34:2015–22.
  21. B. Dharani et.al. Preventing Diabetic Kidney Disease: A Systematic Review Of Current Pharmacological Approaches, International Journal of Applied Pharmaceutics, 2025 ; Vol 17 (1); https://doi.org/10.22159/ijap.2025v17i1.52956
  22. Long-term safety study of Canagliflozin (TA-7284) in combination with GLP-1 analogue in patients with type 2 diabetes mellitus. https://clinicaltrials.gov/ct2/show/NCT02227849. Accessed 5 Sept 2016.